B-cell & Hematologic Antigens

Cat. No.

AT0089

CAS No.

216503-57-0

Alemtuzumab

Synonyms: Campath-IH

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody engineered to bind specifically to interleukin-13 (IL-13), effectively neutralizing its activity. This antibody is extensively utilized in the study of diseases characterized by IL-13 involvement, including asthma, atopic dermatitis, and pulmonary fibrosis. Tralokinumab's targeted mechanism of action and specificity for IL-13 make it a valuable tool in immunological and inflammatory research contexts.

Cat. No.

AT0369

CAS No.

1256258-86-2

Inclacumab

Synonyms: Anti-Human selectin P Recombinant Antibody

Inclacumab is a recombinant human monoclonal IgG4 antibody that exhibits high selectivity for P-selectin, with a dissociation constant (Kd) of 9.9 nM. This antibody effectively inhibits the interaction between P-selectin and its ligand, P-selectin glycoprotein ligand 1 (PSGL-1), with a half-maximal inhibitory concentration (IC50) of 1.9 μg/mL. It is particularly effective in blocking cell adhesion mediated by P-selectin, making it a valuable tool for research into inflammatory and cardiovascular diseases where P-selectin plays a key role.

Cat. No.

AT0488

CAS No.

1826831-79-1

Talacotuzumab

Synonyms: JNJ 56022473; CSL 362

Talacotuzumab (JNJ 56022473; CSL 362) is a fully humanized IgG1 monoclonal antibody engineered to neutralize CD123. It exhibits dissociation constants (K_Ds) of 0.43 nM for CD123, 188 nM for CD32b/c, 46 nM for CD16-158F, and 16.8 nM for CD16-158V, indicating high specificity and affinity for these targets. The antibody effectively inhibits interleukin-3 (IL-3) binding to CD123, thereby blocking IL-3 mediated signaling pathways in targeted cells. The Fc region of Talacotuzumab has been specifically mutated to enhance its affinity for CD16 (FcγRIIIa), which significantly amplifies its capability to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This modification enhances its therapeutic potential, particularly in oncology applications. In vivo studies demonstrate that Talacotuzumab significantly reduces leukemic cell proliferation in acute myeloid leukemia (AML) xenograft mouse models, highlighting its potential as a therapeutic agent in hematological malignancies.

Cat. No.

AT0554

CAS No.

152923-56-3

Daclizumab

Synonyms: Zenapax; Ro 24-7375

Daclizumab (Zenapax) is a humanized monoclonal antibody designed to specifically target and block CD25, the α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA). By reversibly binding to CD25, Daclizumab inhibits the interaction between interleukin-2 (IL-2) and its receptor, thereby modulating the immune response. This antibody is primarily utilized in research focused on multiple sclerosis, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions in this disease.

Cat. No.

AT0559

CAS No.

356547-88-1

Belimumab

Synonyms: LymphoStat B

Belimumab, also known as LymphoStat-B, is a humanized IgG1λ monoclonal antibody designed to target and neutralize B-lymphocyte stimulator (BLyS) protein. By antagonizing the activity of BLyS, Belimumab is utilized in the study of autoimmune disorders and B-cell malignancies. This antibody is particularly relevant for research focused on systemic lupus erythematosus (SLE), providing a valuable tool for understanding and potentially modulating disease mechanisms.

Cat. No.

AT0928

CAS No.

1864871-20-4

Cusatuzumab

Synonyms: ARGX-110

Cusatuzumab (ARGX-110) is a humanized monoclonal antibody targeting CD70. It exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) and effectively blocks the CD70/CD27 signaling pathway. By inhibiting this pathway, cusatuzumab reduces the population of leukemia stem cells (LSCs) and induces gene signatures associated with myeloid differentiation and apoptosis. This antibody is particularly useful in research focused on the pathophysiology and potential therapeutic interventions for leukemia.

Cat. No.

AT0970

CAS No.

1690318-25-2

Crizanlizumab

Crizanlizumab is a monoclonal antibody that targets P-selectin, effectively inhibiting its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). By blocking this interaction, Crizanlizumab plays a crucial role in preventing vaso-occlusive crises (VOCs), making it a valuable tool for the study and research of sickle cell disease pathophysiology and therapeutic interventions.

Cat. No.

AT1338

CAS No.

174722-30-6

Keliximab

Synonyms: SB-210396; IDEC CE9.1

Keliximab (SB-210396) is a chimeric human/macaque IgG1 monoclonal antibody targeting CD4 with a dissociation constant (Ki) of 1.0 nM for soluble CD4. This antibody effectively blocks T-cell proliferation and inhibits the production of interleukin-2 (IL-2), mechanisms critical in the immune response. Due to its specific action on T-cells, Keliximab is extensively utilized in oncological research to study the modulation of the immune system in the tumor microenvironment.